Literature DB >> 28817841

[Practical use of continuous apomorphine infusion via pump].

Lars Tönges1, Andrés Ceballos-Baumann2, Holger Honig3, Alexander Storch4, Wolfgang H Jost5.   

Abstract

Parkinson's disease is the second most common neurodegenerative illness after Alzheimer's disease. In its advanced stages, it is characterized by various special symptoms. In addition to non-motor signs, motor complications are most prominent and most often can only be inadequately improved with pulsatile oral therapies. However, with the aid of continuous dopaminergic stimulation, improvements can be achieved even in advanced stages of the disease. This will not only alleviate motor and non-motor symptoms, but will also lead to a better quality of life. In this context, continuous subcutaneous apomorphine administration by means of a pump has been well established. Its benefits, indications, limitations and practical implementation will be thoroughly described in the expert recommendation. Particularly noteworthy is the rather broad therapeutic window of apomorphine pump treatment, which can be optimally utilized by simple drug titration in a rapidly reversible process. This article presents the results of an expert meeting on apomorphine therapy which took place on July 6, 2016, in Frankfurt (M), Germany. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28817841     DOI: 10.1055/s-0043-110095

Source DB:  PubMed          Journal:  Fortschr Neurol Psychiatr        ISSN: 0720-4299            Impact factor:   0.752


  3 in total

1.  Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.

Authors:  Daniel Richter; Dirk Bartig; Wolfgang Jost; Christoph Jörges; Britta Stumpe; Ralf Gold; Christos Krogias; Lars Tönges
Journal:  J Neural Transm (Vienna)       Date:  2019-06-20       Impact factor: 3.575

Review 2.  [Pharmacological treatment of motor symptoms in Parkinson's diseases].

Authors:  W H Jost
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

Review 3.  Implications of dopaminergic medication withdrawal in Parkinson's disease.

Authors:  J Koschel; K Ray Chaudhuri; L Tönges; M Thiel; V Raeder; W H Jost
Journal:  J Neural Transm (Vienna)       Date:  2021-07-29       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.